NVCR - NovoCure GAAP EPS of -$0.46 beats by $0.07 revenue of $127.32M misses by $1.44M
2023-10-26 07:10:40 ET
More on NovoCure
- NovoCure: TTFields' Ovarian Trial Short-Circuits (Rating Downgrade)
- NovoCure Limited: Record Losses, Falling Margins, And Downward Momentum
- NovoCure: Uncertain Regulatory Path And Slowing Growth
- HC Wainwright cuts NovoCure to neutral in wake of failed study
For further details see:
NovoCure GAAP EPS of -$0.46 beats by $0.07, revenue of $127.32M misses by $1.44M